2025
Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-transit melanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatientsInpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.
Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, op2400788. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsOverall survivalICI administrationSolid malignanciesPatients treated with immune checkpoint inhibitorsAdministration of immune checkpoint inhibitorsMultivariate Cox proportional hazards model analysisResponse to ICI therapyCox proportional hazards model analysisProportional hazards model analysisAdvanced solid malignanciesKaplan-Meier methodOutcomes of patientsInstitutional electronic medical recordsHazards model analysisCox proportional hazards modelsProportional hazards modelCheckpoint inhibitorsICI therapyMedian OSICI initiationICI useRetrospective studyClinical outcomesClinicodemographic variables
2024
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J, Jiang M, Mankbadi M, Wang P, Zaman S, Lee S, Im Y, Feher A, Liu Y, S. S, Tao W, Wei W, Baldassarre L. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLOS ONE 2024, 19: e0314555. PMID: 39621799, PMCID: PMC11611253, DOI: 10.1371/journal.pone.0314555.Peer-Reviewed Original ResearchConceptsAdverse cardiovascular eventsICI therapyCardiac magnetic resonanceIncreased risk of mortalityICI initiationIncreased riskRisk of mortalityCentral nervous systemVentricular dysfunctionCancer patients treated with ICIsCardiovascular eventsLeft ventricular late gadolinium enhancementMortality benefitCardiovascular riskAbnormal left ventricular ejection fractionPatients treated with ICIsLeft ventricular ejection fractionCentral nervous system malignanciesRisk of adverse cardiovascular eventsImmune checkpoint inhibitorsRight ventricular dysfunctionGlobal longitudinal strainVentricular ejection fractionLeft ventricular dysfunctionMultimodality cardiac imagingSuccessful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyAnti-IL-17A antibodyAdverse eventsAnti-PD-1 antibody monotherapyInterleukin (IL)-17/IL-23 axisPsoriatic arthritisImmune checkpoint inhibitor treatmentPD-1 antibody therapyResponse to ICI therapyImmune-related adverse eventsIL-23/IL-17 axisImmune checkpoint inhibitor exposureIL-17/23 axisAnti-CTLA-4Checkpoint inhibitor therapyCell renal cell carcinomaAnti-IL-17AAnti-IL-23 antibodyAssociated with adverse eventsPre-existing psoriasisAnti-tumor efficacyIL-23/IL-17Renal cell carcinomaICI therapyA phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Christenson E, Mahadevan D, Kazmi S, Manda S, Sohal D, Hutson T, Fu S, Martz A, Kordahi S, Barbu E, Flies D, Langermann S, Chisamore M, Gutierrez M, Matrana M, Spira A, Wadlow R, Guha U, Myint H, Le D. A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Journal Of Clinical Oncology 2024, 42: 2538-2538. DOI: 10.1200/jco.2024.42.16_suppl.2538.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune cell infiltrationOvarian cancerColorectal cancerICI therapyCell infiltrationAdvanced metastatic colorectal cancerPromote immune cell infiltrationResistance to ICI therapyEffector memory T cellsPeripheral blood immunophenotypingPhase 1b/2 studyDose of pembrolizumabData cut-offMetastatic colorectal cancerMetastatic solid tumorsMemory T cellsColorectal cancer subjectsImmune cell functionHuman IgG1 Fc domainAnti-tumor activityTumor extracellular matrixModified toxicity probability intervalExtracellular matrixCheckpoint inhibitorsThe Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne E, Fick C, Isbell J, Chaft J, Altorki N, Park B, Spicer J, Forde P, Gomez D, Iyengar P, Harpole D, Stinchcombe T, Liberman M, Bott M, Adusumilli P, Huang J, Rocco G, Jones D. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2024, 118: 119-129. PMID: 38316378, PMCID: PMC11194155, DOI: 10.1016/j.athoracsur.2024.01.024.Peer-Reviewed Original ResearchResected non-small cell lung cancerNon-small cell lung cancerAdvanced non-small cell lung cancerImmune checkpoint inhibitorsPhase III trialsCell lung cancerICI therapyPerioperative immunotherapyIII trialsLocally advanced non-small cell lung cancerTreatment of resectable non-small cell lung cancerLung cancerLong-term survival of patientsPathologic complete response rateUnited States Food and Drug Administration approvalRandomized phase III trialClinical trials of immunotherapyTreatment of non-small cell lung cancerFood and Drug Administration approvalImpairs surgical outcomesComplete response rateSignificant survival benefitTrials of immunotherapySurvival of patientsDrug Administration approval
2023
New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.
Shafi S, Challa B, Parwani A, Aung T. New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives. Cutis 2023, 112: e32-e39. PMID: 38091429, DOI: 10.12788/cutis.0911.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLymphocyte-activating gene-3Early phase clinical trialsPrimary treatment failureAggressive skin cancerNew therapeutic agentsICI therapyCheckpoint inhibitorsNovel immunotherapiesMelanoma patientsTreatment failureMetastatic melanomaPredictive biomarkersLong-term benefitsClinical trialsClinical careNew therapiesTherapeutic strategiesAlternative treatmentSkin cancerTherapy outcomeTherapeutic agentsNovel targetNovel therapeuticsPatientsPotential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
Wang Y, Lu L, Ling C, Zhang P, Han R. Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors. Nutrients 2023, 15: 3984. PMID: 37764768, PMCID: PMC10537481, DOI: 10.3390/nu15183984.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1/PD-L1 inhibitorsPD-L1 inhibitorsICI therapyDietary interventionBC patientsBreast cancerTherapeutic strategiesNovel immune checkpoint inhibitorsHDAC2 inhibitorsIntegrated therapeutic strategiesOptimal clinical benefitKaplan-Meier plotter platformNew therapeutic strategiesAnti-cancer effectsCheckpoint inhibitorsSupportive therapyClinical benefitHigh morbidityCombination therapyTreatment outcomesLethal malignancyTherapeutic effectEffective treatmentPrognostic analysisCardiothoracic complications of immune checkpoint inhibitors
Gosangi B, Wang Y, Rubinowitz A, Kwan J, Traube L, Gange C, Bader A. Cardiothoracic complications of immune checkpoint inhibitors. Clinical Imaging 2023, 102: 98-108. PMID: 37659356, DOI: 10.1016/j.clinimag.2023.08.001.Peer-Reviewed Educational MaterialsConceptsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsOverall survivalTumor responseAdverse effectsDevelopment of irAEsNovel adverse effectsImproved overall survivalOverall patient outcomesICI administrationHematologic malignanciesPatient outcomesSolid tumorsIrAEsCancer treatmentGreater mortalityComplicationsTherapySurvivalInhibitorsMyocarditisPneumonitisPatientsMalignancyChanges in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety ScaleUltrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, McDaniel T, Trent J, Baehner F, Murtaza M, Pal S. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology 2023, 7: e2200543. PMID: 37027813, PMCID: PMC10309555, DOI: 10.1200/po.22.00543.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaPartial responseComplete responseVariant allele fractionRenal cell carcinomaCell carcinomaCtDNA analysisImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyDiscontinuation of immunotherapyDepth of responseICI therapyNivolumab monotherapyEligible patientsRadiographic progressionInhibitor therapyPeripheral bloodDisease progressionCtDNA assessmentSubsequent progressionPatientsMultiple indicationsSingle time pointPatient-specific mutationsSecondary objectiveSarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.Peer-Reviewed Original ResearchImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyPulmonary toxicityEosinophilic asthmaAirway diseaseImmune related adverse eventsPD-1 inhibitor pembrolizumabSevere eosinophilic asthmaRelated adverse eventsICI therapyInhibitor pembrolizumabPD-1Benign courseTreatment cessationFatal complicationCase reportAdverse eventsSarcoidosisTherapyPneumonitisAirwayPatientsToxicityAsthma
2022
Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.
Fenton S, Zannikou M, Ilut L, Fischietti M, Ji C, Oku C, Horvath C, Le Poole I, Bosenberg M, Bartom E, Kocherginsky M, Platanias L, Saleiro D. Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors. Molecular Cancer Research 2022, 21: 332-344. PMID: 36573964, PMCID: PMC10073316, DOI: 10.1158/1541-7786.mcr-22-0684.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmunosuppressive genesCheckpoint inhibitorsImmunostimulatory genesAnti-programmed cell death protein 1 therapyPharmacologic inhibitionIFNγ-induced expressionMelanoma cellsMajority of patientsTreatment of patientsTreatment of melanomaMelanoma tumor growthDrug target inhibitionICI therapyDurable responsesPatient survivalMetastatic melanomaPatient outcomesPoor survivalResponse rateTumor growthIFNγOverexpression of ULK1Context-dependent mannerMelanomaProceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, Bellizzi A, Basu Roy U, Bradshaw G, Edwards R, El-Gabry E, Elvin J, Gajewski T, McShane L, Oberley M, Philip R, Rimm D, Rosenbaum J, Rubin E, Schlager L, Sherwood S, Stewart M, Taube J, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022, 6: e2200454. PMID: 36446042, PMCID: PMC10530621, DOI: 10.1200/po.22.00454.Peer-Reviewed Original ResearchConceptsICI therapyImmune checkpoint inhibition therapyDeath ligand 1 (PD-L1) expressionMultiple predictive biomarkersTumor biomarker testsCheckpoint inhibition therapyLigand 1 expressionDeath ligand 1Field of oncologyICI benefitPredictive factorsPredictive biomarkersInhibition therapyNeoantigen expressionBiomarker testsHealth insurance organizationsUS FoodDrug AdministrationAmerican PathologistsMedicaid ServicesTherapyBiomarker developmentNational InstituteLigand 1Clinical applicationMyasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management
Zubair A, Roy B, Baehring J, Nowak R. Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. Cureus 2022, 14: e30638. PMID: 36439604, PMCID: PMC9683636, DOI: 10.7759/cureus.30638.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitor therapyMyasthenia gravisCheckpoint inhibitorsInhibitor therapyICI therapyImmune checkpoint inhibitor therapyImmune checkpoint inhibitor useInflammatory adverse effectsBest treatment algorithmCell lung cancerCheckpoint inhibitor useRenal cell cancerSystem side effectsPotential treatment optionNeurologic complicationsInhibitor useAcute managementOncologic treatmentAnti-CTLA4Cell cancerClinical outcomesTreatment algorithmClinical manifestationsTreatment optionsThe Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
Riaz F, Zhu H, Cheng W, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Parikh R, Reuss J, Prsic E, Doroshow D. The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.28_suppl.300.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsRetrospective studyInpatient settingOutcome studiesPT outcomesStage IV solid malignancyYale-New Haven HospitalImaging-based responseMedian prior linesNon-curative intentOutcome of ptsCTLA-4 inhibitorsMulticenter retrospective studyPD-L1 expressionPoor clinical outcomeCare of patientsTime of administrationMount Sinai HospitalGeorgetown University HospitalHealth care systemICI administrationICI doseICI initiationImmune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatientsMutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma
Shi Y, Xie T, Wang B, Wang R, Cai Y, Yuan B, Gleber-Netto FO, Tian X, Rodriguez-Rosario AE, Osman AA, Wang J, Pickering CR, Ren X, Sikora AG, Myers JN, Rangel R. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Communications Biology 2022, 5: 757. PMID: 35902768, PMCID: PMC9334280, DOI: 10.1038/s42003-022-03675-4.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaTumor immune microenvironmentCold tumor immune microenvironmentSquamous cell carcinomaICI therapyOSCC modelCell carcinomaImmune microenvironmentCold tumorsCell death protein 1 (PD-1) inhibitorsCancer cell-intrinsic mechanismsImmune checkpoint inhibitor therapyOral squamous cell carcinomaCheckpoint inhibitor therapyCombination ICI treatmentEffective immunotherapeutic approachesInterferon genes (STING) agonistImmunosuppressive M2 macrophagesProtein 1 inhibitorTobacco-associated cancersICI responsivenessICI treatmentCell-intrinsic mechanismsImmunotherapeutic approachesInhibitor therapyProgrammed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC
Fernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC. Journal Of Thoracic Oncology 2022, 17: 1078-1085. PMID: 35764237, DOI: 10.1016/j.jtho.2022.06.007.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHigh negative predictive valueLow stage patientsICI therapyPD-L1Negative predictive valueAdjuvant settingLong-term benefitsPredictive valueProgrammed Death Ligand 1PD-L1 mRNA levelsCurrent predictive biomarkersHigh PD-L1Death ligand 1Lung cancer managementPD-L1 mRNAUseful objective methodReal-time reverse transcription-polymerase chain reactionMRNA levelsStandard of careReverse transcription-polymerase chain reactionQuantitative real-time reverse transcription-polymerase chain reactionTranscription-polymerase chain reactionMRNA expression levelsAdvanced NSCLCChoice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 combined positive scoreTumor proportion scorePD-L1Gastric cancerImmune cellsPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentBackgroundImmune checkpoint inhibitorsGastric cancer immunotherapyPD-L1 positivityPD-L1 scoringPD-L1 immunohistochemistryDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceCheckpoint inhibitorsDako 22C3ICI therapyCross-sectional studyCancer immunotherapyPatient selection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply